Basic HTML Version
94
SCIENTIFIC REPORT 2012
Title:
Phase II study, multicenter, double blind, randomized, in two parts, to evaluate the
efficacy and safety of pertuzumab in combination with standard chemotherapy versus
placebo plus standard chemotherapy, in women with recurrent ovarian epithelial cancer,
platinum-resistant, with low HER3 expression in mRNA.
District Attorney:
F. Hoffmann-La Roche Ltd.
Principal Investigator:
Yolanda Garcia Garcia.
Title:
Randomized, open and multicenter phase II clinical trial to determine toxicity and
efficacy of pre-surgical chemotherapy with or without Bevaciizumab in cancer patients
Advanced Ovary.
District Attorney:
Spanish Ovarian Cancer Research Group (GEICO).
Principal Investigator:
Yolanda Garcia Garcia.
Title:
Phase III, multicenter, randomized clinical trial to compare the efficacy of the addition
of cytoreduction surgery to chemotherapy versus cancer-exclusive chemotherapy
of ovarian recurrence of the sensitive to platinum.
District Attorney:
GEICO.
Principal Investigator:
Yolanda Garcia Garcia.
Title:
Post - authorization, observational, prospective, multicenter longitudinal study for
to evaluate the percentage of prostate cancer patients treated with analogue of the
LHRHs that show resistance to castration (CPRC) after a follow-up period of 3
years.
District Attorney:
Ipsen Pharma SA
Principal Investigator:
José Luis González Sala.
Title:
Phase IIIb open-label study of regorafenib in patients with colorectal cancer (CRC)
metastatic patients who have progressed to conventional treatments.
District Attorney:
Bayer Healthcare AG.
Principal Investigator:
Carles Pericay Pajaume.
Title:
Open phase II study of ultra-selection of patients using genotyping technology
new generation for the Folfiri + Panitumumab regimen in cancer patients
irinotecan - resistant stage IV colorectal disease without detectable mutations using
high sensitivity for the detection of mutations in the KRAS, PIK3Ca BRAF and NRAS genes.
District Attorney:
Digestive Tumors Treatment Group.
Principal Investigator:
Carles Pericay Pajaume.